Understanding Melanotan-1 Mechanism and Receptor Selectivity Melanotan-1 (afamelanotide, [Nle4-D-Phe7]--MSH) is a synthetic analog of alpha-melanocyte-stimulating hormone (-MSH), engineered with amino acid substitutions at positions 4 and 7 that increase receptor binding affinity and extend serum half-life to approximately 33 minutes following subcutaneous injection
Semaglutide Dosing Guide In-depth dosing protocols, clinical trial data, and pharmacokinetics
(As compared to GLP1-RA use, in observational new user cohort study from Denmark.) Just published in @DiabetologiaJnl #epitwitter #SGLT2i Full paper: link.springer.com/article/10.100 Thank you to @kidney_boy, Joel Topf, for inspiring us to look at this research question and to @aishaikh, @edgarvlermamd, @ChristosArgyrop, and @asupadh who provided their input in the original thread!#AskRenal Is there data looking at how SGLT2i affects urinary stone profile
Ongoing research is exploring new formulations, such as oral semaglutide, and dual agonists such as tirzepatide